SEC Form 4 · accession 0001104659-16-097851
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Glickman
Officer — Chief Commercial Officer
Period of report
Feb 12, 2016
Accepted (ET)
Feb 17, 2016 · 9:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Feb 12, 2016 | A | 86,863 | $0.00 | A | 116,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Long-Term Incentive Plan, which vest 25% annually over four years commencing upon the first anniversary of the Reporting Person's date of hire, subject to continued employment or service to the Company.